Regulation of phosphatase homologue of tensin protein expression by bone morphogenetic proteins in prostate epithelial cells

Prostate

Volumn 71, Issue 8, 2011, Pages 791-800

  Jerde, Travis J ^a   Wu, Zhong ^b   Theodorescu, Dan ^b   Bushman, Wade ^c  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Bone morphogenetic protein; Epithelium; Phosphatase homologue of tensin analogue; Prostate; Protein stability

Indexed keywords

BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 4; CYCLOHEXIMIDE; DOXYCYCLINE; PHOSPHATASE HOMOLOGUE OF TENSIN; PROTEIN KINASE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; GROWTH INHIBITION; HUMAN; HUMAN CELL; LINKAGE ANALYSIS; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROSTATE EPITHELIUM CELL; PROTEIN EXPRESSION; PROTEIN STABILITY; SIGNAL TRANSDUCTION; TRANSLATION INITIATION; TUMOR SUPPRESSOR GENE;

BONE MORPHOGENETIC PROTEIN 4; CELL DIFFERENTIATION; CELL LINE; CELL PROLIFERATION; HUMANS; MALE; PROSTATE; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN STABILITY; PTEN PHOSPHOHYDROLASE; RNA, SMALL INTERFERING;

EID: 79953695672     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21295     Document Type: Article

References (39)

1. Sircar K, Yoshimoto M, Monzon FA, Koumakpayi IH, Katz RL, Khanna A, Alvarez K, Chen G, Darnel AD, Aprikian AG, Saad F, Bismar TA, Squire JA. PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer. J Pathol 2009;8(4):505-513.
2. Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 1999; 96(8):4240-4245. (Pubitemid 29190320)
3. Groszer M, Erickson R, Scripture-Adams DD, Lesche R, Trumpp A, Zack JA, Kornblum HI, Liu X, Wu H. Negative regulation of neural stem/progenitor cell proliferation by the Pten tumor suppressor gene in vivo. Science 2001;294:2186-2189. (Pubitemid 33150679)
4. Halvorsen OJ, Haukaas SA, Akslen LA. Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer. Clin Cancer Res 2003;9(4):1474-1479. (Pubitemid 36418404)
5. Frost RA, Lang CH. Protein kinase B/Akt: A nexus of growth factor and cytokine signaling in determining muscle mass. J Appl Physiol 2007;103(1):378-387.
6. Arcaro A, Aubert M, Espinosa del Hierro ME, Khanzada UK, Angelidou S, Tetley TD, Bittermann AG, Frame MC, Seckl MJ. Critical role for lipid raft-associated Src kinases in activation of PI3K-Akt signalling. Cell Signal 2007;19(5):1081-1092.
7. Xia H, Nho RS, Kahm J, Kleidon J, Henke CA. Focal adhesion kinase is upstream of phosphatidylinositol 3-kinase/Akt in regulating fibroblast survival in response to contraction of type I collagen matrices via a beta 1 integrin viability signaling pathway. J Biol Chem 2004;279(31):33024-33034. (Pubitemid 39014762)
8. Ozes ON, Akca H, Mayo LD, Gustin JA, Maehama T, Dixon JE, Donner DB. A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1. Proc Natl Acad Sci USA 2001;98(8):4640-4645. (Pubitemid 32295029)
9. Prins GS, Putz O. Molecular signaling pathways that regulate prostate gland development. Differentiation 2008;76(6):641-659. (Pubitemid 352032742)
10. Gazzerro E, Canalis E. Bone morphogenetic proteins and their antagonists. Rev Endocr Metab Disord 2006;7:51-65. (Pubitemid 46044349)
11. Lamm ML, Podlasek CA, Barnett DH, Lee J, Clemens JQ, Hebner CM, Bushman W. Mesenchymal factor bone morphogenetic protein 4 restricts ductal budding and branching morphogenesis in the developing prostate. Dev Biol 2001;232:301-314. (Pubitemid 32337095)
12. Grishina IB, Kim SY, Ferrara C, Makarenkova HP, Walden PD. BMP7 inhibits branching morphogenesis in the prostate gland and interferes with Notch signaling. Dev Biol 2005;288(2):334-347. (Pubitemid 41790747)
13. Miyazaki H, Watabe T, Kitamura T, Miyazono K. BMP signals inhibit proliferation and in vivo tumor growth of androgenin-sensitive prostate carcinoma cells. Oncogene 2004;23(58):9326-9335. (Pubitemid 40069665)
14. Brubaker KD, Corey E, Brown LG, Vessella RL. Bone morphogenetic protein signaling in prostate cancer cell lines. J Cell Biochem 2004;91(1):151-160.
15. Kim IY, Lee DH, Lee DK, Ahn HJ, Kim MM, Kim SJ, Morton RA. Loss of expression of bone morphogenetic protein receptor type II in human prostate cancer cells. Oncogene 2004;23(46):7651-7659. (Pubitemid 39424923)
16. Tamguney T, Stokoe D. New insights into PTEN. J Cell Sci 2007;120:4071-4079.
17. Engin H, Baltali E, Güler N, Güler G, Tekuzman G, Uner A. Expression of PTEN, cyclin D1, P27/KIP1 in invasive ductal carcinomas of the breast and correlation with clinicopathological parameters. Bull Cancer 2006;93(2):E21-E26.
18. Li DM, Sun H. TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res 1997;57:2124-2129. (Pubitemid 27247025)
19. Stiles BL. Phosphatase and tensin homologue deleted on chromosome 10: Extending its PTENtacles. Int J Biochem Cell Biol 2009;41(4):757-761.
20. Waite KA, Eng C. BMP2 exposure results in decreased PTEN protein degradation and increased PTEN levels. Hum Mol Genet 2003;12(6):679-684. (Pubitemid 36372494)
21. Beck SE, Carethers JM. BMP suppresses PTEN expression via RAS/ERK signaling. Cancer Biol Ther 2007;6(8):1313-1317. (Pubitemid 351590388)
22. Schwarze SR, DePrimo SE, Grabert LM, Fu VX, Brooks JD, Jarrard DF. Novel pathways associated with bypassing cellular senescence in human prostate epithelial cells. J Biol Chem 2002;277(17):14877-14883. (Pubitemid 34952561)
23. Hayward SW, Dahiya R, Cunha GR, Bartek J, Deshpande N, Narayan P. Establishment and characterization of an immortalized but non-transformed human prostate epithelial cell line: BPH-1. In Vitro Cell Dev Biol Anim 1995;31(1):14-24.
24. Wu Z, Conaway M, Gioeli D, Weber MJ, Theodorescu D. Conditional expression of PTEN alters the androgen responsiveness of prostate cancer cells. Prostate 2006;66(10):1114-1123. (Pubitemid 43939216)
25. Jerde TJ, Bushman W. IL-1 induces IGF-dependent epithelial proliferation in prostate development and reactive hyperplasia. Sci Signal 2009;2(86):ra49.
26. Wu Z, McRoberts KS, Theodorescu D. The role of PTEN in prostate cancer cell tropism to the bone micro-environment. Carcinogenesis 2007;28(7):1393-1400. (Pubitemid 47241787)
27. Rahdar M, Inoue T, Meyer T, Zhang J, Vazquez F, Devreotes PN. A phosphorylation-dependent intramolecular interaction regulates the membrane association and activity of the tumor suppressor PTEN. Proc Natl Acad Sci USA 2009;106(2):480-485.
28. Miyazaki Y, Oshima K, Fogo A, Ichikawa I. Evidence that bone morphogenetic protein 4 has multiple biological functions during kidney and urinary tract development. Kidney Int 2003;63(3):835-844. (Pubitemid 36315561)
29. Cook C, Vezina CM, Allgeier SH, Shaw A, Yu M, Peterson RE, Bushman W. Noggin is required for normal lobe patterning and ductal budding in the mouse prostate. Dev Biol 2007;312(1):217-230. (Pubitemid 350182443)
30. Darby S, Cross SS, Brown NJ, Hamdy FC, Robson CN. BMP-6 over-expression in prostate cancer is associated with increased Id-1 protein and a more invasive phenotype. J Pathol 2008;214(3):394-404. (Pubitemid 351212395)
31. Masuda H, Fukabori Y, Nakano K, Shimizu N, Yamanaka H. Expression of bone morphogenetic protein-7 (BMP-7) in human prostate. Prostate 2004;59(1):101-106. (Pubitemid 38387847)
32. Feeley BT, Gamradt SC, Hsu WK, Liu N, Krenek L, Robbins P, Huard J, Lieberman JR. Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer. J Bone Miner Res 2005;20(12):2189-2199. (Pubitemid 41698782)
33. Yang S, Zhong C, Frenkel B, Reddi AH, Roy-Burman P. Diverse biological effect and Smad signaling of bone morphogenetic protein 7 in prostate tumor cells. Cancer Res 2005;65(13):5769-5777. (Pubitemid 40911180)
34. Ye L, Lewis-Russell JM, Kynaston H, Jiang WG. Endogenous bone morphogenetic protein-7 controls the motility of prostate cancer cells through regulation of bone morphogenetic protein antagonists. J Urol 2007;178:1086-1091. (Pubitemid 47211048)
35. Feeley BT, Krenek L, Liu N, Hsu WK, Gamradt SC, Schwarz EM, Huard J, Lieberman JR. Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions. Bone 2006; 38(2):154-166. (Pubitemid 43165781)
36. Dai J, Keller J, Zhang J, Lu Y, Yao Z, Keller ET. Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism. Cancer Res 2005; 65(18):8274-8285. (Pubitemid 41330592)
37. Shukla S, Maclennan GT, Hartman DJ, Fu P, Resnick MI, Gupta S. Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion. Int J Cancer 2007;121(7):1424-1432. (Pubitemid 47328700)
38. Gu J, Tamura M, Pankov R, Danen EH, Takino T, Matsumoto K, Yamada KM. Shc and FAK differentially regulate cell motility and directionality modulated by PTEN. J Cell Biol 1999;146(2):389-403. (Pubitemid 29369775)
39. Theodorescu D, Laderoute KR, Gulding KM. Epidermal growth factor receptor-regulated human bladder cancer motility is in part a phosphatidylinositol 3-kinase-mediated process. Cell Growth Differ 1998;9(11):919-928. (Pubitemid 28514287)